Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Travere Therapeutics Q1 2024 Adj EPS $(1.51) Misses $(0.99) Estimate, Sales $41.374M Miss $42.847M Estimate

Author: Benzinga Newsdesk | May 06, 2024 04:13pm
Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(1.51) per share which missed the analyst consensus estimate of $(0.99) by 52.53 percent. This is a 64.13 percent decrease over losses of $(0.92) per share from the same period last year. The company reported quarterly sales of $41.374 million which missed the analyst consensus estimate of $42.847 million by 3.44 percent. This is a 33.95 percent increase over sales of $30.888 million the same period last year.

Posted In: TVTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist